Gilead Sciences, Inc.
Address: Foster City, CA
Business sector:
biological products
Gilead Sciences, Inc. financial information:
People related to Gilead Sciences, Inc.:
John F. Cogan - director
Etienne F. Davignon - director
Carla A. Hills - director
Kevin E. Lofton - director
John W. Madigan - director
John C. Martin - chairman & CEO
John F. Milligan - president & COO
Nicholas G. Moore - director
Robin L. Washington - SVP & CFO
Richard J. Whitley - director
Gayle E. Wilson - director
Other current Gilead Sciences, Inc. relationships:
Akin, Gump, Strauss, Hauer & Feld, LLP - lobby firm
BGR Group - lobby firm
East End Group, LLC - lobby firm
Foley Hoag - lobby firm
Podesta Group - lobby firm
Rubicon Advisors LLC - lobby firm
Gilead Sciences, Inc. past relationships:
Paul Berg - director
Jeffrey W. Bird - SVP
CV Therapeutics Inc. - acquirer
DCI Group, LLC - lobby firm
James M. Denny - director
Gordon E. Moore - director
Mark L. Perry - senior business adviser
Donald H. Rumsfeld - chairman
George P. Shultz - director
http://www.gilead.com/about/leadership/senior-leadership
John C. Martin, PhD
Chairman and Chief Executive Officer
John F. Milligan, PhD
President and Chief Operating Officer
Norbert W. Bischofberger, PhD
Executive Vice President, Research and Development and Chief Scientific Officer
Robin L. Washington
Executive Vice President and Chief Financial Officer
Gregg H. Alton
Executive Vice President, Corporate and Medical Affairs
Paul R. Carter
Executive Vice President, Commercial Operations
John McHutchison, MD
Executive Vice President, Clinical Research
Katie L. Watson
Senior Vice President, Human Resources
http://www.muckety.com/Per-Wold-Olsen/197370.muckety
Per Wold-Olsen
Age in 2014: 66
Areas of interest:
biological products industry
pharmaceuticals industry
Personal social network: Much of Wold-Olsen's Muckety comes from business connections.
Per Wold-Olsen current relationships:
Gilead Sciences, Inc. - director
Per Wold-Olsen past relationships:
Merck - division president
Barron's - 3 days ago
Gilead investors shouldn't overreact to Merck's $3.8 billion purchase of Idenix and its Hepatitis C portfolio.
---------------------------------------------------------------
With GILEAD setting the price of $1,000 a day for 84-day treatment, the competition is not forcing the price low, but pushing it higher.
---------------------------------------------------------------
The Republican Healthcare Plan is the same as the Nazi Healthcare Plan for Old Jews...
... in fact, with 300,000,000 poor people infected with Hepatitis-C worldwide, Gilead will participate in killing more people than Hitler's SS ever dreamed of.
It costs $2 per gram to make Gilead's wonder drug, and one gram is two and a half day's supply. It costs less than $80 to make this $84,000 treatment.
No comments:
Post a Comment